General Information of Drug (ID: DMGK1JE)

Drug Name
MORAb-004 Drug Info
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 2 [1]
Melanoma 2C30 Phase 2 [1]
Merkel cell carcinoma 2C34 Phase 2 [2]
Sarcoma 2A60-2C35 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMGK1JE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Endosialin (CD248)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ontuxizumab DM0FJIE Melanoma 2C30 Phase 2 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endosialin (CD248) TTYJWT7 CD248_HUMAN Modulator [3]

References

1 ClinicalTrials.gov (NCT01574716) Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 15;21(6):1281-8.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)